EvlaBio AG

EvlaBio is a biotech company developing a first-in-class therapy to address Left Ventricular Hypertrophy (LVH) in the setting of chronic kidney disease (CKD), a critical unmet medical need affecting millions worldwide.
CKD affects more than 10% of the global population. LVH prevalence increases with CKD progression, affecting approximately 30-45% of patients in early stages and up to 75-80% of patients on dialysis. Cardiovascular disease remains the leading cause of mortality in this patient population.
EvlaBio's lead program, EVLA-101, is a monoclonal antibody targeting FGFR4 to block FGF23-driven cardiac signalling, with the aim of inhibiting the development and progression of LVH in patients with CKD.